Human genome editing and moral leadership: findings of the WHO Expert Advisory Committee
By Peter Mills,
Nuffield Council on Bioethics
| 07. 14. 2021
Assistant Director Pete Mills gives his reaction to the much-anticipated reports of the World Health Organization's Expert Advisory Committee on Developing Global Standards for Governance and Oversight of Human Genome Editing
In 2019, the World Health Organization convened an Expert Advisory Committee on Developing Global Standards for Governance and Oversight of Human Genome Editing. On Monday it published its findings in three reports: a position paper (summarising the findings), a set of recommendations and a framework for governance. These documents represent a significant contribution to the literature around genome editing that has emerged since about 2015, which includes a number of major reports and a steady stream of statements and position papers emanating from learned societies, professional bodies, national ethics committees and ad hoc groups. [1] The WHO report is both the latest of the ‘big reports’ and the last in the pipeline. For now.
The scope of the ‘big reports’ on human genome editing differs: the WHO covers laboratory research, medical uses and reproductive uses, or ‘somatic’, ‘germline’ and ‘heritable’ genome editing. The reports also have different emphases. The Nuffield Council has, naturally, been concerned with ethical, social and political matters. There was an implied division of labour between the International Commission (which reported in 2020) and the WHO Committee...
Related Articles
By Mariella Bodemeier Loayza Careaga, The Scientist | 03.15.2024
Scientists have genetically modified isolated microbes for decades. Now, using CRISPR, they intend to target entire microbiomes.
Humans are never alone. Even in a room devoid of other people, they are always in the company of billions of microscopic beings...
By Gerry Smith, Bloomberg | 03.12.2024
When Celenise Mahmood first learned about two new gene therapies that could cure sickle cell disease, she felt a wave of relief.
Her 9-year-old son, Navid, has the inherited blood disorder. By age 5, he’d had over 30 life-saving blood...
By Carol Cardona and Michelle Kromm, Scientific American | 03.11.2024
By Nada Hassanein, New Jersey Monitor | 03.14.2024
The U.S. Food and Drug Administration late last year approved two breakthrough gene therapies for sickle cell disease patients. Now a new federal program seeks to make these life-changing treatments available to patients with low incomes — and it could...